GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (NAS:TMDX) » Definitions » Net Cash per Share
中文

TransMedics Group (TransMedics Group) Net Cash per Share : $-5.33 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is TransMedics Group Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). TransMedics Group's Net Cash per Share for the quarter that ended in Dec. 2023 was $-5.33.

The historical rank and industry rank for TransMedics Group's Net Cash per Share or its related term are showing as below:

During the past 8 years, the highest Price-to-Net-Cash Ratio of TransMedics Group was 21.05. The lowest was 6.98. And the median was 15.59.

TMDX's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 6.81
* Ranked among companies with meaningful Price-to-Net-Cash only.

TransMedics Group Net Cash per Share Historical Data

The historical data trend for TransMedics Group's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransMedics Group Net Cash per Share Chart

TransMedics Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial 1.42 2.85 0.91 3.47 -5.33

TransMedics Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.47 3.10 1.14 -4.16 -5.33

Competitive Comparison of TransMedics Group's Net Cash per Share

For the Medical Devices subindustry, TransMedics Group's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TransMedics Group's Price-to-Net-Cash Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where TransMedics Group's Price-to-Net-Cash falls into.



TransMedics Group Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

TransMedics Group's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(394.812-568.845-0)/32.6708
=-5.33

TransMedics Group's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(394.812-568.845-0)/32.6708
=-5.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TransMedics Group  (NAS:TMDX) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


TransMedics Group Net Cash per Share Related Terms

Thank you for viewing the detailed overview of TransMedics Group's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TransMedics Group (TransMedics Group) Business Description

Traded in Other Exchanges
Address
200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body.
Executives
Tamer I Khayal officer: Chief Commercial Officer TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
Miriam Provost officer: VP of US Regulatory & FDA Rel. 2000 MINUTEMAN ROAD, ANDOVER MA 01810
Waleed H Hassanein director, officer: President & CEO TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Stephen Gordon officer: Chief Financial Officer 200 MINUTEMAN ROAD, ANDOVER MA 01810
David Weill director 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Anil P. Ranganath officer: See Remarks C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Edward M Basile director 200 MINUTEMAN ROAD, ANDOVER MA 01810
John F Carey officer: VP of Operations 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Nicholas Corcoran officer: See Remarks C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Laura Damme officer: VP, Clinical Affairs C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Stephanie Lovell director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kania Edwin M Jr director
Rakesh P. Godhani officer: Chief Digital Officer C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
John F Sullivan officer: VP of Quality & Engineering 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810